A pioneer in medicine and leadership, Freda Lewis-Hall, MD, DFAPA, MFPM has been on the frontlines of healthcare for more than 40 years as a clinician, researcher, and leader in the biopharmaceuticals and life sciences industries. A passionate advocate for health equity and improved outcomes for all patients, Dr. Lewis-Hall served in multiple leadership positions in the pharmaceutical industry. She is widely regarded for expanding outreach to patients, reshaping the focus on patient engagement and inclusion, improving health information and education, and amplifying the voice of the patient within company culture and decision-making.

Dr. Anne C. Beal, is the Chief Patient Officer at Sanofi. She is responsible for integrating the patient voice and priorities into all aspects of Sanofi’s work to facilitate development of healthcare solutions that truly meet patients’ needs. Dr. Beal joined Sanofi from PCORI, where she was the Deputy Exec Dir, Chief Officer for Engagement and the inaugural COO. Prior to PCORI, she was president of The Aetna Foundation, the charitable arm of Aetna, and previously directed programs on Quality of Care for Underserved Populations at the Commonwealth Fund.

Dr. Janet Woodcock began her long and distinguished FDA career in 1986. In 1994, Dr. Woodcock was named Director of the CDER. In that position, she has led many of the FDA’s groundbreaking drug initiatives. In 2020 Dr. Woodcock was asked to lend her expertise to “Operation Warp Speed” the initiative to develop therapeutics in response to the pandemic. Dr. Woodcock was named Acting Commissioner of Food and Drugs on January 20, 2021-February 17, 2022. Dr. Woodcock is now the FDA's Principal Deputy Commissioner. In this role she works closely with the Commissioner of Food and Drugs to develop and implement key public health initiatives and helps oversee the agency’s day-to-day functions.